Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.

NCT02840721 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: PF-06480605

Sponsor

Telavant, Inc.

Collaborators

[object Object]